1. Lee AWM, Ng WT, Chan JYW, et al. (2019) Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev, 79: 101890. DOI: 10.1016/j.ctrv.2019.101890 [DOI:10.1016/j.ctrv.2019.101890]

2. Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, et al. (2023) Recurrent/metastatic nasopharyngeal carcinoma treatment from present to future: where are we and where are we heading? Curr Treat Options Oncol, 24(9): 1138-1166. DOI: 10.1007/s11864-023-01101-3 [DOI:10.1007/s11864-023-01101-3]

3. Nazeer F, Poulose JV, Kainickal CT (2022) Induction chemotherapy in nasopharyngeal carcinoma - A systematic review of phase III clinical trials. Cancer Treat Res Commun, 32: 100589. DOI: 10.1016/j.ctarc.2022.100589 [DOI:10.1016/j.ctarc.2022.100589]

4. Fan Y, Hui M, Li F, et al. (2024) Establishment of nomogram prediction model for distant metastasis of nasopharyngeal carcinoma after radiotherapy. Int J Radiat Res, 22(2): 373-378. DOI: 10.61186/ijrr.22.2.373 [DOI:10.61186/ijrr.22.2.373]

5. You R, Liu Y-P, Huang P-Y, et al. (2020) Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: A multicenter phase 3 randomized clinical trial. JAMA Oncol, 6(9): 1345-1352. DOI: 10.1001/jamaoncol.2020.1808 [DOI:10.1001/jamaoncol.2020.1808]

6. Natasya Naili MN, Hasnita CH, Shamim AK, et al. (2010) Chromosomal alterations in Malaysian patients with nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Cancer Genet Cytogenet, 203(2): 309-12. DOI: 10.1016/j.cancergencyto.2010.07.136 [DOI:10.1016/j.cancergencyto.2010.07.136]

7. Smith ER, Wang J-Q, Yang D-H, Xu X-X (2022) Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat, 65: 100881. DOI: 10.1016/j.drup.2022.100881 [DOI:10.1016/j.drup.2022.100881]

8. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 20(7): 924-937. DOI: 10.1016/S1470-2045(19)30167-6 [DOI:10.1016/S1470-2045(19)30167-6]

9. Yuan Y, Lee JS, Yost SE, et al. (2021) Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with triple-negative breast cancer. Oncologist, 26(3): e382-e393. DOI: 10.1002/onco.1357 [DOI:10.1002/onco.13574]

10. Parisi A, Palluzzi E, Cortellini A, et al. (2020) First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Clin Transl Oncol, 22(1): 158-162. DOI: 10.1007/s12094-019-02122-x [DOI:10.1007/s12094-019-02122-x]

11. Huang Y, Yan D, Wang M, et al. (2021) Clinicopathological factors affecting the prognosis of massive hemorrhage after radiotherapy for patients having nasopharyngeal carcinoma. J Cancer Res Ther, 17(5): 1219-1224. DOI: 10.4103/jcrt.jcrt_586_21 [DOI:10.4103/jcrt.jcrt_586_21]

12. Liu L, Hu L, Zeng Q, Peng D, Chen Z, Huang C, et al. (2021) Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: correlation of quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters with hypoxia-inducible factor 1α expression and tumor grade/stage. Ann Palliat Med, 10(2): 2238-2253. DOI: 10.21037/apm-21-303 [DOI:10.21037/apm-21-303]

13. Hengrui L (2023) An example of toxic medicine used in traditional Chinese medicine for cancer treatment. J Tradit Chin Med, 43(2): 209-210. DOI: 10.19852/j.cnki.jtcm.2023.02.001

14. Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, et al. (2022) Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. J Hematol Oncol, 15(1): 165. DOI: 10.1186/s13045-022-01383-4 [DOI:10.1186/s13045-022-01383-4]

15. Baloche V, Ferrand FR, Makowska A, et al. (2020) Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. Expert Opin Ther Targets, 24(6): 545-558. DOI: 10.1080/14728222.2020.1751820 [DOI:10.1080/14728222.2020.1751820]

16. Mai HQ, Chen QY, Chen D, et al. (2021) Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med, 27(9): 1536-1543. DOI: 10.1038/s41591-021-01444-0 [DOI:10.1038/s41591-021-01444-0]

17. Twu CW, Lin PJ, Tsou HH, et al. (2022) Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma. Head Neck, 44(6): 1453-1461. DOI: 10.1002/hed.27044 [DOI:10.1002/hed.27044]

18. Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, et al. (2022) Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol, 8(5): 706-714. DOI: 10.1001/jamaoncol.2022.0122 [DOI:10.1001/jamaoncol.2022.0122]

19. Takeshita N, Enokida T, Okano S, et al. (2022) Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study. Front Oncol, 12: 951387. DOI: 10.3389/fonc.2022.951387 [DOI:10.3389/fonc.2022.951387]

20. Luo DH, Li XY, Guo SS, et al. (2023) Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA-IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial. Lancet Reg Health West Pac, 40: 100895. DOI: 10.1016/j.lanwpc.2023.100895 [DOI:10.1016/j.lanwpc.2023.100895]

21. Sharifi-Rad J, Quispe C, Patra JK, et al. (2021) Paclitaxel: Application in modern oncology and nanomedicine-based cancer therapy. Oxid Med Cell Longev, 2021: 3687700. DOI: 10.1155/2021/3687700 [DOI:10.1155/2021/3687700]

22. Liu H and Li Y (2022) Potential roles of Cornichon family AMPA receptor auxiliary protein 4 (CNIH4) in head and neck squamous cell carcinoma. Cancer Biomark, 35(4): 439-450. DOI: 10.3233/CBM-220143 [DOI:10.3233/CBM-220143]

23. Ke LR, Xia WX, Qiu WZ, et al. (2017) A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma. Oral Oncol, 70: 7-13. DOI: 10.1016/j.oraloncology.2017.04.018 [DOI:10.1016/j.oraloncology.2017.04.018]

24. Thawani R, Gao L, Mohinani A, Tudorica A, Li X, Mitri Z, et al. (2022) Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. BMC Med Imaging, 22(1): 182. DOI: 10.1186/s12880-022-00908-0 [DOI:10.1186/s12880-022-00908-0]

25. Militello C, Rundo L, Dimarco M, et al. (2022) 3D DCE-MRI radiomic analysis for malignant lesion prediction in breast cancer patients. Acad Radiol, 29(6): 830-40. DOI: 10.1016/j.acra.2021.08.024 [DOI:10.1016/j.acra.2021.08.024]

26. Filella X, Rodríguez-Garcia M, Fernández-Galán E (2022) Clinical usefulness of circulating tumor markers. Clin Chem Lab Med, 61(5): 895-905. DOI: 10.1515/cclm-2022-1090 [DOI:10.1515/cclm-2022-1090]

27. Jiang M, Chen P, Guo X, et al. (2023) Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag. EJNMMI Res, 13(1): 27. DOI: 10.1186/s13550-023-00976-5 [DOI:10.1186/s13550-023-00976-5]

28. Choi KH, Yu M, Jeong S, Lee JH (2020) Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis. Int J Clin Oncol, 25(7): 1405-1411. DOI: 10.1007/s10147-020-01664-3 [DOI:10.1007/s10147-020-01664-3]

29. Gebhart P, Singer CF, Gschwantler-Kaulich D. (2023) CA125 Levels in BRCA mutation carriers - a retrospective single center cohort study. BMC Cancer, 23(1): 610. DOI: 10.1186/s12885-023-11116-6 [DOI:10.1186/s12885-023-11116-6]

30. Li S, Pi G, Zeng Y, et al. (2022) Notoginsenoside R1 induces oxidative stress and modulates LPS induced immune microenvironment of nasopharyngeal carcinoma. Int Immunopharmacol, 113(Pt A): 109323. DOI: 10.1016/j.intimp.2022.109323 [DOI:10.1016/j.intimp.2022.109323]

31. Qiu W, Jiang J, Zhan Z, et al. (2022) Prognostic impact of pretreatment serum superoxide dismutase activity in patients with locoregionally advanced nasopharyngeal carcinoma. Int J Biol Markers, 37(1): 21-30. DOI: 10.1177/17246008221075042 [DOI:10.1177/17246008221075042]

32. Gao H, Xie R, Huang R, et al. (2022) CIRBP regulates pancreatic cancer cell ferroptosis and growth by directly binding to p53. J Immunol Res, 2022: 2527210. DOI: 10.1155/2022/2527210 [DOI:10.1155/2022/2527210]

33. Amina G, Hasnae D, Imane EA, et al. (2022) Assessment of lipid peroxidation status in the serum of Moroccan patients with nasopharyngeal carcinoma. Contemp Oncol (Pozn), 26(4): 253-258. DOI: 10.5114/wo.2023.124498 [DOI:10.5114/wo.2023.124498]

34. Chen L, Hu CS, Chen XZ, et al. (2012) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol, 13(2): 163-71. DOI: 10.1016/S1470-2045(11)70320-5. [DOI:10.1016/S1470-2045(11)70320-5]